ArticleMolecular biology reports2025
Unveiling the spectrum of vancomycin resistance in Staphylococcus aureus from Hospital-acquired urinary tract infections (HA-UTI) in cardiac patients.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with cardiac disease are highly susceptible to hospital-acquired urinary tract infections (HA-UTI) due to immunosuppression, invasive procedures, and prolonged hospitalization. Although Enterobacteriaceae are frequent pathogens, the contribution of vancomycin-resistant Staphylococcus aureus (VRSA) remains unexplored. Among 11 known glycopeptide resistance genes (vanA, vanB, vanD, vanF, vanI, vanM, vanC, vanE, vanG, vanL, and vanN), vanA and vanB are most commonly reported. However, the diversity of other van genes and their interplay with antimicrobial resistance (AMR) and virulence determinants are poorly characterized. METHODS AND
resultsBetween March 2020 and April 2022, 189 cardiac ward patients were screened for VRSA-associated HA-UTI. The presence of van genes, efflux pump genes (norA, norB, sepA, mepA, mdeA), and virulence genes (hla, sea, icaA, fnbA) was determined using singleplex PCR, correlation analysis, and qRT-PCR for expression profiling. Antimicrobial susceptibility was assessed via disk diffusion, minimum inhibitory concentration (MIC), hierarchical clustering, and multiple antibiotic resistance indexing. 55% of VRSA isolates harboured limited van gene diversity, with vanA predominant. These isolates exhibited extensive AMR, high vancomycin MICs (> 256 µg/mL), and multidrug resistance. Co-occurrence of efflux pump genes (norA + norB, norB + norC, sepA + norB) and virulence genes (hla + sea, icaA + fnbA) showed significant positive correlations. All isolates were susceptible to linezolid and chloramphenicol.
conclusionvanA-mediated resistance in VRSA from HA-UTI is strongly associated with efflux pump activity and virulence gene expression. Integrative genomic and transcriptomic approaches are essential for deciphering these networks, guiding precision therapeutics, and strengthening infection control measures.
Indexed as
Identifiers
41065916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.